NICOTINE AND METABOLITES, UR | |
| This test is a lab developed test. For further information, see the Compliance Remarks section below. |
| Synonyms | Nicotine and Metabolites, Urine, Quantitative; 3-Hydroxycotinine; Anabasine; Cotinine; Nicotine and Cotinine, LC/MS/MS, Urine; Nornicotine; Pain Management | | SPECIMEN REQUIREMENTS | | | Container Type | Leakproof plastic urine container | | Supply Item Number |  1387 | | Specimen Type | Random urine | | Preferred Volume | 4 mL | | Emergency Minimum Volume | 1 mL | | Specimen Processing | Transfer 4 mL with no additives or preservatives urine to a standard PAML aliquot tube. | | Store and Transport | Refrigerated | | Stability | Room Temp 1 week Refrigerated 2 weeks Frozen (-20 °C) 1 month | | Unacceptable Condition | Specimens exposed to more than 3 freeze/thaw cycles | | CPT Codes | 80323, (HCPCS G0480) | | Interface Order Code | 83887.Z16 | | Billing Code | NICMUR | | Test Schedule | Tue, Thu | | Turnaround Time | 1-5 days | | Method | Tandem Mass Spectrometry | | Reference Ranges | | Title | Descriptor | Ranges | Units | | Nicotine | Non-smoker | < 2 | ng/mL | | Cotinine | Non-smoker | < 5 | ng/mL | | 3-OH-Cotinine | Non-smoker | < 50 | ng/mL | | Nornicotine | Non-smoker | < 2 | ng/mL | | Anabasine | Non-smoker | < 10 | ng/mL | | | > 100 ng/mL Nicotine indicates use of tobacco products and or nicotine replacement therapy. | | > 200 ng/mL Cotinine indicates use of tobacco products and or nicotine replacement therapy. Cotinine is the major metabolite of nicotine. | | > 50 ng/mL 3-OH-Cotinine indicates use of tobacco products and or nicotine replacement therapy. 3-OH-Cotinine is a metabolite of Cotinine. | | > 30 ng/mL of Nornicotine indicates use of tobacco products and/or nicotine replacement therapy. | | > 10 ng/mL Anabasine indicates use of tobacco products. Anabasine is not present in nicotine replacement therapy products such as transdermal patches, gum, nasal sprays and inhalers. |
| | Compliance Remarks | This test was developed and its performance characteristics determined by PAML. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. PAML is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing. | | Notes | Useful for determination of active or passive nicotine use or for differentiation between nicotine replacement and tobacco use. |
| Interface Codes | | type | order code | test description | result code | result description | units | decimal places | loinc code | | o | 83887.Z16 | Nicotine and Metabolites, Ur | | r | 83887.Z16 | Nicotine and Metabolites, Ur | 83887.Z11 | Nicotine, Urine | ng/mL | | 3854-7 | | r | 83887.Z16 | Nicotine and Metabolites, Ur | 83887.Z12 | Cotinine, Urine | ng/mL | | 10366-3 | | r | 83887.Z16 | Nicotine and Metabolites, Ur | 83887.Z13 | 3-OH-Cotinine, Urine | ng/mL | | 33916-8 | | r | 83887.Z16 | Nicotine and Metabolites, Ur | 83887.Z14 | Nornicotine, Urine | ng/mL | | 33917-6 | | r | 83887.Z16 | Nicotine and Metabolites, Ur | 83887.Z15 | Anabasine, Urine | ng/mL | | 33915-0 |
v1.0|1101|3|1|0 |
|
1387